Bradykinin Contributes to Vasogenic Edema in Murine Experimental Cerebral Malaria

This study demonstrates that bradykinin-mediated vasogenic edema, driven by the kallikrein-kinin system, significantly contributes to the pathogenesis of cerebral malaria in both human patients and murine models, suggesting that inhibiting this pathway can protect against neurologic deterioration and improve survival.

The Gist

The Big Picture: A Traffic Jam and a Leaky Dam

Imagine the brain as a highly secure, high-tech city. To keep the city safe, there is a massive, impenetrable wall surrounding it called the Blood-Brain Barrier (BBB). This wall keeps the "bad guys" (toxins, parasites, and excess fluid) out while letting the "good guys" (oxygen and nutrients) in.

In Cerebral Malaria, a deadly form of malaria, the brain gets attacked. The problem isn't just the malaria parasite itself; it's that the city's walls start to crumble, and water floods in. This swelling (edema) is what kills the patient.

This paper asks a simple question: What is the specific "saboteur" causing the walls to crumble?

The researchers discovered that the saboteur is a tiny, short-lived chemical messenger called Bradykinin (BK). Think of Bradykinin as a "Demolition Crew" that arrives at the wall, punches holes in it, and lets the floodwaters in.

---

The Investigation: Finding the Culprit

The researchers looked at two groups:

1. Real Patients: Children in Kenya with severe malaria.
2. Lab Models: Mice infected with a similar type of malaria.

Clue #1: The "Broken Glass" Evidence

When the Demolition Crew (Bradykinin) does its job, it leaves behind a specific type of trash: Cleaved Kininogen (cHK).

• The Analogy: Imagine a high-quality glass window (High Molecular Weight Kininogen). When the Demolition Crew smashes it, you don't just see the hole; you see the shards of glass on the floor.
• The Finding: The researchers found these "glass shards" (cHK) in the blood of 40% of the Kenyan children with severe brain malaria, but almost none in children with mild malaria. In the mice, all the sick mice had these shards. This proved the Demolition Crew was active.

Clue #2: Who is the Boss of the Demolition Crew?

Bradykinin doesn't just appear out of nowhere. It needs a boss to release it. The researchers tested several suspects to see who was the "Boss":

1. Suspect A: Factor XII (The Alarm System): Usually, this starts the chain reaction.
   • The Test: They removed Factor XII from the mice.
   • The Result: The mice still got sick. The alarm system wasn't the main culprit here.
2. Suspect B: The Parasite's Own Tools: They thought the parasite might be breaking the glass directly.
   • The Test: They used a parasite that couldn't make its own "glass-breaking" tool.
   • The Result: The mice still got sick. The parasite wasn't doing the smashing directly.
3. Suspect C: The "Vessel Wall Manager" (PRCP): This is a protein sitting on the inside of the blood vessels.
   • The Test: They removed this manager from the brain's blood vessels in the mice.
   • The Result: Bingo! The mice stayed healthy. Their brain walls didn't crumble, and they survived.
   • The Conclusion: The "Vessel Wall Manager" (PRCP) was the one activating the Demolition Crew (Bradykinin).

Clue #3: The Receptors (The Doors)

Once the Demolition Crew (Bradykinin) is released, it needs a door to enter the wall and break it. These doors are called B1 and B2 Receptors.

• The Test: They locked the doors (removed the receptors) in the mice.
• The Result: Even though the Demolition Crew was released, it couldn't get in to break the wall. The mice survived!

---

The Breakthrough: A New Treatment Strategy

Currently, the only treatment for cerebral malaria is Artesunate, a drug that kills the malaria parasite.

• The Problem: It takes time for the drug to kill the parasite. By the time the parasite is gone, the "Demolition Crew" has already flooded the brain, and the patient has died or suffered brain damage.

The New Idea: What if we treat the symptom (the flooding) at the same time we treat the cause (the parasite)?

The researchers tested a "double attack":

1. Artesunate: Kills the parasite.
2. A Kallikrein Inhibitor (RZLT7824): This is a drug that stops the "Vessel Wall Manager" (PRCP) from releasing the Demolition Crew. It essentially locks the demolition crew in the basement so they can't break the wall.

The Result:

• Mice treated with only the parasite killer: Many died, and their brains were swollen.
• Mice treated with the double attack: 65% survived (compared to 38% with just the parasite killer). Their brains were less swollen, and they behaved normally.

---

Why This Matters (The Takeaway)

Think of cerebral malaria like a house fire.

• The Parasite is the spark.
• The Brain Swelling is the fire spreading and destroying the house.
• Artesunate is the fire extinguisher that puts out the spark.
• The Bradykinin System is the gasoline that makes the fire spread so fast.

Right now, doctors only have the fire extinguisher. They are trying to put out the spark, but the gasoline (Bradykinin) is making the fire too big to handle before the spark is gone.

This paper suggests we need a "Fire Retardant" (the Kallikrein Inhibitor) to stop the gasoline from spreading. By adding this new drug to the current treatment, we might save more children's lives and prevent the brain damage that leaves survivors with learning disabilities.

Summary in One Sentence

This study found that a specific chemical pathway (the Bradykinin system) acts like a demolition crew that breaks down the brain's protective walls during malaria, and blocking this pathway alongside standard treatment could save more lives and protect the brain.

Technical Summary

1. Problem Statement

Cerebral malaria (CM), caused by Plasmodium falciparum, is a leading cause of death in African children. Despite effective anti-parasitic therapy (artesunate), mortality remains high, and survivors often suffer from severe neurocognitive deficits. A critical pathological feature of CM is progressive brain swelling due to vasogenic edema (breakdown of the blood-brain barrier, BBB). The proximal mechanisms initiating this edema are not fully understood. While previous studies suggested a role for endothelial activation, the specific molecular pathways driving BBB leakage remain a major unmet therapeutic target. The authors hypothesize that the plasma kallikrein/kinin system (KKS), specifically the release of the vasoactive peptide bradykinin (BK), mediates this vasogenic edema.

2. Methodology

The study employed a dual approach combining clinical human data and extensive murine experimental models:

• Human Clinical Samples:

  • Plasma was collected from Kenyan children presenting with Central Nervous System Malaria (CNS-M), uncomplicated malaria (UM), acute febrile non-malarial illness (AFN), and healthy controls.
  • Biomarkers: Plasma levels of High Molecular Weight Kininogen (HK), cleaved HK (cHK, a marker of BK generation), and BK were analyzed.
  • Techniques: Competitive ELISA for total HK, immunoblotting for cHK fragments (56/46 kDa), and LC-MS/MS for BK quantification.

• Murine Experimental Cerebral Malaria (ECM) Model:

  • Infection: C57BL/6J mice were infected with Plasmodium berghei ANKA (PbA).
  • Genetic Models: The study utilized various knockout (KO) and hypomorph mice to dissect the KKS pathway:
    • Kng1-/- (Total kininogen deficiency).
    • Bdkrb1-/- and Bdkrb2-/- (BK receptor knockouts), including double KO.
    • Klkb1-/- (Prekallikrein deficiency).
    • F12-/- (Factor XII deficiency).
    • Prcpgt/gt (Prolylcarboxypeptidase hypomorphs).
    • Prcpfl/fl Cre (Conditional brain endothelial-specific PRCP knockout).
  • Pharmacological Intervention: Wild-type mice were treated with:
    • RZLT7824: A selective plasma kallikrein (PKa) inhibitor.
    • PrCP Inhibitor: A selective prolylcarboxypeptidase inhibitor.
    • Artesunate + RZLT7824: Adjuvant therapy mimicking clinical scenarios.
  • Outcome Measures:
    • Neurologic Deterioration: Assessed via SHIRPA scores.
    • Brain Edema: Quantified by Evans Blue dye extravasation (BBB permeability) and brain mass.
    • Survival: Kaplan-Meier analysis.
    • Parasitemia: Measured via flow cytometry.

3. Key Contributions

• Identification of BK as a Driver of CM Edema: The paper establishes that the kallikrein/kinin system is activated during cerebral malaria, leading to bradykinin release and subsequent vasogenic edema.
• Discovery of a Novel Activation Mechanism: The study identifies Prolylcarboxypeptidase (PRCP) on brain endothelial cells as a critical activator of prekallikrein, operating independently of the traditional Factor XII (FXII) pathway in the context of ECM.
• Therapeutic Validation: It demonstrates that inhibiting plasma kallikrein (PKa) or its activator (PRCP) significantly protects against neurologic deterioration and brain edema, even without reducing parasitemia.
• Adjuvant Therapy Proof-of-Concept: The study provides the first evidence that combining a PKa inhibitor with standard artesunate therapy significantly improves survival and neurologic outcomes in a severe malaria model.

4. Key Results

• Human Findings:

  • 40% of children with CNS-M had detectable plasma cleaved HK (cHK), compared to only 18% of those with uncomplicated malaria.
  • cHK levels (a stable marker of prior BK release) were significantly higher in CNS-M patients at admission and decreased after recovery.
  • This confirms that BK generation occurs in human CM, though it is not a universal marker (likely due to timing of sample collection).

• Murine ECM Findings:

  • Activation: PbA-infected mice showed elevated BK levels, reduced HK and prekallikrein levels, and the presence of cHK, indicating active KKS consumption.
  • Genetic Protection:
    • Protected: Kng1-/-, Bdkrb1-/-/Bdkrb2-/- (double KO), Bdkrb2-/-, Bdkrb1-/-, Klkb1-/-, Prcpgt/gt, and brain-specific Prcpfl/fl Cre mice all showed significantly reduced neurologic deterioration, reduced brain edema (Evans Blue), and increased survival compared to wild-type mice.
    • Not Protected: F12-/- mice showed only a minor reduction in edema and no significant protection from neurologic deterioration, indicating that FXII is not the primary driver in this model.
  • Mechanism: The absence of PRCP (the endothelial activator of prekallikrein) recapitulated the protection seen in prekallikrein knockouts, confirming PRCP's role in activating the KKS in the brain vasculature.
  • Parasite Protease: Silencing the parasite cysteine protease berghepain-2 did not protect mice, ruling out direct parasite proteolysis of HK as the primary mechanism.

• Pharmacological & Adjuvant Results:

  • Treatment with the PKa inhibitor RZLT7824 alone reduced edema and improved survival.
  • Combination Therapy: In mice with established neurologic deterioration (Day 5), adding RZLT7824 to artesunate treatment resulted in:
    • Significantly improved SHIRPA scores (neurologic function).
    • Reduced brain Evans Blue uptake and brain mass.
    • Increased survival from 38% (artesunate alone) to 65% (artesunate + PKa inhibitor).

5. Significance

• Pathophysiological Insight: The study shifts the understanding of CM pathogenesis by highlighting the kallikrein/kinin system as a central mediator of BBB breakdown and vasogenic edema, distinct from the parasite biomass itself.
• Therapeutic Implication: It suggests that current anti-parasitic treatments are insufficient because they do not address the host-mediated inflammatory edema. Adjuvant therapy targeting the KKS (specifically PKa or PRCP) could be a life-saving strategy for children with cerebral malaria.
• Clinical Relevance: Since plasma kallikrein deficiency is a benign condition in humans and PKa inhibitors are already FDA-approved for Hereditary Angioedema (HAE), repurposing these drugs for cerebral malaria is a feasible and potentially rapid translational pathway.
• Model Specificity: The study clarifies that while the mechanism of edema (BK-mediated) may be shared between human CM and murine ECM, the activation trigger differs (PRCP-driven in mice vs. potentially multifactorial in humans involving FXII or parasite proteases), yet the downstream therapeutic target (PKa/BK) remains valid.

In conclusion, this paper provides robust evidence that bradykinin-induced vasogenic edema is a critical driver of cerebral malaria mortality and that inhibiting the kallikrein/kinin system offers a promising adjunctive therapeutic strategy to improve survival and neurologic outcomes.